488.58
+12.71(+2.67%)
Currency In USD
| Previous Close | 475.87 |
| Open | 471.22 |
| Day High | 491.91 |
| Day Low | 471.22 |
| 52-Week High | 496.98 |
| 52-Week Low | 265 |
| Volume | 397,810 |
| Average Volume | 365,888 |
| Market Cap | 10.84B |
| PE | -37.87 |
| EPS | -12.9 |
| Moving Average 50 Days | 434.83 |
| Moving Average 200 Days | 348.4 |
| Change | 12.71 |
If you invested $1000 in Madrigal Pharmaceuticals, Inc. (MDGL) 10 years ago, it would be worth $23,265.71 as of November 07, 2025 at a share price of $488.58. Whereas If you bought $1000 worth of Madrigal Pharmaceuticals, Inc. (MDGL) shares 5 years ago, it would be worth $3,831.4 as of November 07, 2025 at a share price of $488.58.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025
GlobeNewswire Inc.
Oct 28, 2025 12:00 PM GMT
Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of RezdiffraPoster of distinction examines the impact of Rezdiffra interrupt
Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025
GlobeNewswire Inc.
Oct 22, 2025 12:00 PM GMT
CONSHOHOCKEN, Pa., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today th
Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire Inc.
Sep 03, 2025 12:00 PM GMT
CONSHOHOCKEN, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Morgan Stanley 23rd Annual Global Health Care Conference on Monday, Sept. 8, 2025 at 7:45 A